Clinics (Sao Paulo). 2017 January; 72(1): 58-64.
Copyright © 2017 CLINICS
The Third Xiangya Hospital of Central South University, Department of Nephrology, Changsha 410013, China.
The Third Xiangya Hospital of Central South University, Medical Intensive Care Unit, Changsha 410013, China.
*Corresponding author. E-mail:
received September 23, 2016; revised October 20, 2016; accepted October 20, 2016.
The aim of this study was to evaluate the benefits and risks of omega-3 fatty acid supplementation in patients with chronic kidney disease. A systematic search of articles in PubMed, Embase, the Cochrane Library, and reference lists was performed to find relevant literature. All eligible studies assessed proteinuria, the serum creatinine clearance rate, the estimated glomerular filtration rate, or the occurrence of end-stage renal disease. Standard mean differences with 95% confidence intervals for continuous data were used to estimate the effects of omega-3 fatty acid supplementation on renal function, as reflected by the serum creatinine clearance rate, proteinuria, the estimated glomerular filtration rate, and relative risk. Additionally, a random-effects model was used to estimate the effect of omega-3 fatty acid supplementation on the risk of end-stage renal disease. Nine randomized controlled trials evaluating 444 patients with chronic kidney disease were included in the study. The follow-up duration ranged from 2 to 76.8 months. Compared with no or low-dose omega-3 fatty acid supplementation, any or high-dose omega-3 fatty acid supplementation, respectively, was associated with a lower risk of proteinuria (SMD: -0.31; 95% CI: -0.53 to -0.10;
Keywords: Omega-3 Fatty Acid, Adjunctive Therapy, Chronic Kidney Disease, Meta-analysis
Articles from Clinics are provided here courtesy of
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo